Toward better dialysis compatibility: Advances in the biochemistry and pathophysiology of the peritoneal membranes

Kidney International

Volumn 61, Issue 2, 2002, Pages 375-386

  Miyata, Toshio ^a,b   Devuyst, Olivier ^a,b   Kurokawa, Kiyoshi ^a,b   Van Ypersele de Strihou, Charles ^a,b  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Advanced glycation end products; Angiogenesis; Carbonyl stress; Effective peritoneal surface area; Glucose degradation products; Nitric oxide; Ultrafiltration failure; Vascular endothelial growth factor

Indexed keywords

2,4 DINITROPHENYLHYDRAZINE; 3 DEOXYGLUCOSONE; 4 HYDROXYNONENAL; ALDEHYDE DERIVATIVE; AQUAPORIN 1; ARABINOSE; BASIC FIBROBLAST GROWTH FACTOR; BASIC FIBROBLAST GROWTH FACTOR 2; CARBONYL DERIVATIVE; GLUCOSE; GLYOXAL; GLYOXALASE; METHYLGLYOXAL; MITOGEN ACTIVATED PROTEIN KINASE; N(G) METHYLARGININE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; NITROPRUSSIDE SODIUM; PENTOSIDINE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; BIOCHEMISTRY; DIALYSATE; ENZYME ACTIVITY; GENE THERAPY; GLYCATION; HEMODIALYSIS; HISTOPATHOLOGY; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MEMBRANE PERMEABILITY; MOLECULAR BIOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PERITONEAL CAVITY; PERITONEAL DIALYSIS; PERITONITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SOLUTE; STRESS; ULTRAFILTRATION; UREMIA;

EID: 0036151586     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2002.00135.x     Document Type: Article

References (116)

1. Peritoneal dialysis
2. The influence of dialysis treatment modality on the decline of remaining renal function
3. Integration of peritoneal dialysis and transplantation programs
4. The peritoneal membrane in chronic peritoneal dialysis
5. Issues affecting the longevity of the continuous peritoneal dialysis therapy
6. Peritoneal transport characteristics of water, low-molecular weight solutes and proteins during long-term continuous ambulatory peritoneal dialysis
7. Functional characteristics of the peritoneal membrane in long-term continuous ambulatory peritoneal dialysis
8. Functional longevity of the human peritoneum: How long is continuous peritoneal dialysis possible? Results of a prospective median long-term study
9. Increased peritoneal membrane transport is associated with decreased patient and technique survival for continuous peritoneal dialysis patients
10. A prospective study of peritoneal transport in CAPD patients
11. Prevention and treatment of peritoneal dialysis membrane failure
12. The physiology of peritoneal solute transport and ultrafiltration
13. A three-pore model of peritoneal transport
14. Study of the permeability of the isolated dog mesentery
15. Metabolic control of permeability in isolated mesentery
16. Role of transcellular water channels in peritoneal dialysis
17. Water channels in the peritoneum
18. Aquaporin-1 and endothelial nitric oxide synthase expression in capillary endothelia of human peritoneum
19. In vivo inhibition of transcellular water channels (aquaporin-1) during acute peritoneal dialysis in rats
20. Reduced osmotic water permeability of the peritoneal barrier in aquaporin-1 knockout mice
21. Nitric oxide synthases: Roles, tolls, and controls
22. Nitric oxide in renal health and disease
23. Vascular endothelial growth factor (VEGF) and its receptors
24. Biological roles of fibroblast growth factor-2
25. Basic fibroblast growth factor expression is increased in human renal fibrogenesis and may mediate autocrine fibroblast proliferation
26. A comparison of peritoneal transport in patients with psoriasis and uremia
27. Chronic uremia induces permeability changes, increased nitric oxide synthase expression, and structural modification in the peritoneum
28. Immunohistochemical detection of advanced glycosylation end products in the peritoneum and its possible pathophysiological role in CAPD
29. Advanced glycation and lipoxidation of the peritoneal membrane: Respective roles of serum and peritoneal fluid reactive carbonyl compounds
30. Categorization of ultrastructural changes in peritoneal mesothelium, stroma and blood vessels in uremia and CAPD patients
31. Peritoneal sclerosis in peritoneal dialysis patients related to dialysis settings and peritoneal transport properties
32. Neoangiogenesis in the peritoneal membrane
33. Vascular proliferation and enhanced expression of endothelial nitric oxide synthase in human peritoneum exposed to long-term peritoneal dialysis
34. Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis
35. Expression of aquaporin-1 in a long-term peritoneal dialysis patient with impaired transcellular water transport
36. Effects of nitroprusside on peritoneal mass transfer coefficients and microvascular physiology
37. The nitric oxide donor nitroprusside intraperitoneally affects peritoneal permeability in CAPD
38. The effect of a nitric oxide inhibitor (L-NAME) on peritoneal transport during dialysis in rats
39. Developmental expression of NOS isoforms in fetal rat lung: Implications for transitional circulation and pulmonary angiogenesis
40. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not fibroblast growth factor-induced angiogenesis
41. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells
42. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia
43. S-nitrosylation: Spectrum and specificity
44. Expression and regulation of aquaporin-1 and endothelial nitric oxide synthase in relationship with water permeability across the peritoneum
45. Regulation of aquaporin-1 and nitric oxide synthase isoforms in a rat model of acute peritonitis
46. Membrane longevity in peritoneal dialysis: Impact of infection and bio-incompatible solutions
47. Activation of type III nitric oxide synthase in astrocytes following a neurotropic viral infection
48. Glucose degradation product methylglyoxal enhances the production of vascular endothelial growth factor in peritoneal cells: Role in the functional and morphological alterations of peritoneal membranes in peritoneal dialysis
49. Early and advanced glycosylation end products: Kinetics of formation and clearance in peritoneal dialysis
50. Alterations in non-enzymatic biochemistry in uremia: Origin and significance of "carbonyl stress" in long-term uremic complications
51. Structure elucidation of a senescence cross-link from human extracellular matrix
52. wε-car-boxymethyllysine as a degradation product of fructose lysine in glycated protein
53. Mechanism of protein modification by glyoxal and glycolaldehyde, reactive intermediates of the Maillard reaction
54. Advanced glycation and development of diabetic complications: Unifying the involvement of glucose, methylglyoxal and oxidative stress
55. Role of sugar fragmentation in the Maillard reaction
56. Mechanism of autoxidative glycosylation: Identification of glyoxal and arabinose as intermediates in the autoxidative modification of protein by glucose
57. Heat sterilization of fluids for peritoneal dialysis gives rise to aldehydes
58. In vitro biocompatibility of a heat-sterilized, low-toxic, and less acidic fluid for peritoneal dialysis
59. 3-Deoxyglucosone, a promotor of advanced glycation end products in fluids for peritoneal dialysis
60. Carbonyl stress in uremia: Accumulation of carbonyls accelerate the formation of pentosidine, an advanced glycation end product
61. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking
62. 2-Isopropylidenehydrazono-4-oxo-thiazolidin-5-ylacetanilide (OPB-9195) inhibits the neointima proliferation of rat carotid artery following balloon injury: Role of glycoxidation and lipoxidation reactions in vascular tissue damage
63. Mechanism of the inhibitory effect of OPB-9195 [(±)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-ylacetanilide] on advanced lipoxidation end product formation
64. Influence of hemodialysis membrane type on pentosidine plasma level, a marker of "carbonyl stress"
65. Advanced glycation and lipoxidation end products: Role of reactive carbonyl compounds generated during carbohydrate and lipid metabolism
66. Autoxidation products of both carbohydrates and lipids are increased in uremic plasma: Is there oxidative stress in uremia?
67. Advanced oxidation protein products as a novel marker of oxidative stress in uremia
68. Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure
69. Implication of altered redox regulation by antioxidant enzymes in the increased plasma pentosidine, an advanced glycation end product, in uremia
70. Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: Renal implications in the pathophysiology of pentosidine
71. Erythrocyte redox state in uremic anemia: Effects of hemodialysis and relevance of glutathione metabolism
72. Effects of glycerol-induced acute renal failure on tissue glutathione and glutathione-dependent enzymes in the rat
73. Involvement of β2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis: Induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-α and interleukin 1
74. The receptor for advanced glycation endproducts mediates the interaction of AGE-β2-microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway: Implication for the pathogenesis of dialysis-related amyloidosis
75. Advanced glycation end products stimulate mitogen-activated protein kinase and proliferation in rabbit vascular smooth muscle cells
76. Increased aggregation of human platelets produced by advanced glycation end products in vitro
77. Advanced glycation end products increase retinal vascular endothelial growth factor expression
78. β2-Microglobulin modified with advanced glycation end products delays monocyte apoptosis and induces differentiation into macrophage-like cells
79. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins
80. c-src
81. 4-Hydroxynonenal triggers an epidermal growth factor receptor-linked signal pathway for growth inhibition
82. 4-Hydroxynonenal induces Fas-independent redox-related activation of capase-3
83. Glyoxal and methylglyoxal trigger distinct signals for MAP family kinases and caspase activation in human endothelial cells
84. The lipoxidation end product 4-hydroxy-2,3-nonenal up-regulates transforming growth factor β1 expression in macrophage lineage: A link between oxidative injury and fibrosclerosis
85. Carbon monoxide and nitric oxide suppress the hypoxic induction of vascular endothelial growth factor gene via the 5′ enhancer
86. Nitric oxide inhibits the formation of advanced glycation and products
87. Pathophysiological roles of nitric oxide in inflammation
88. Biocompatibility of new peritoneal dialysis solutions: Clinical experience
89. Icodextrin's effects on peritoneal transport
90. Amino acid-based peritoneal dialysis fluids
91. Does removal of glucose lower the carbonyl stress of glucose containing peritoneal dialysis? Effect of dwell time on icodextrin and amino acid PD fluids
92. Reduced 1,2-dicarbonyl compounds in bicarbonate/lactate-buffered peritoneal dialysis (PD) fluids and PD fluids based on glucose polymers or amino acids
93. In vitro biocompatibility of bicarbonate-based peritoneal dialysis solutions
94. Peritoneal dialysis solution biocompatibility: Inhibitory mechanisms and recent studies with bicarbonate-buffered solutions
95. First in vitro and in vivo experiences with stay-safe balance, a pH-neutral solution in a dual-chambered bag
96. ε-(carboxymethyl) lysine and imidazolones under conditions similar to continuous ambulatory peritoneal dialysis
97. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products
98. Bicarbonate/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels
99. Effect of metformin on advanced glycation endproduct formation and peripheral nerve function in streptozotocin-induced diabetic rats
100. In vitro formation of advanced glycation end products in peritoneal dialysis fluid
101. In vivo formation of a Schiff base of aminoguanidine with pyridoxal phosphate
102. Glyoxalase I deficiency is associated with an unusual level of advanced glycation end products in a hemodialysis patient
103. Inhibition of nitric oxide synthase as a potential therapeutic target
104. Nitric oxide synthases: Catalytic function and progress towards selective inhibition
105. Molecular mechanisms and therapeutic strategies related to nitric oxide
106. Pharmacological modulation of nitric oxide synthesis by mechanism-based inactivators and related inhibitors
107. Substrate and inhibitor for nitric oxide synthase during peritoneal dialysis in rabbits
108. Inhibition of nitric oxide synthase reverses changes in peritoneal permeability in a rat model of acute peritonitis
109. Vascular-specific growth factors and blood vessel formation
110. Angiogenesis: Potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation
111. Experimental models in peritoneal dialysis: A European experience
112. Clinical applications of angiogenic growth factors and their inhibitors
113. Genetic modulation of the peritoneal membrane: Potential for improving peritoneal dialysis through gene therapy
114. Ex vivo and in vivo gene transfer to the peritoneal membrane in a rat model
115. Viral vectors for gene therapy: The art of turning infectious agents into vehicles of therapeutics